YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Now that Pfizer is the vaccine front-runner, should you buy the stock?

Posted online

Pfizer stock may be coming out of a pandemic slump, now that it's in pole position for a coronavirus vaccine.

This week, its stock jumped 8% and hit a 52-week high of nearly $42, before settling down some. 

The question remains whether a vaccine development ultimately would have a significant impact on the pharmaceutical giant’s bottom line. A key factor is how many other companies are standing at the finish line with vaccines of their own.

Read more from Fortune.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Annual downtown holiday events combine for Nov. 21 celebration

Organizers hope to bolster client traffic to center city businesses.

Most Read
SBJ.net Poll
How often do you use artificial intelligence for your business?

*

View results

Update cookies preferences